Effectiveness and safety of zuberitamab in membranous nephropathy patients : a multicenter retrospective study

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/beb6a8dc29ea92b4c9cf69ca67a355cf.pdf
Effectiveness and safety of zuberitamab in membranous nephropathy patients : a multicenter retrospective study

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Junjun
Zhang
Dan Yu yd20135620237@126.com The first Affiliated Hospital of Zhengzhou University Department of Nephrology zhengzhou China -
Junjun Zhang zhangjj0123@126.com The first Affiliated Hospital of Zhengzhou University Department of Nephrology zhengzhou China *
Zhanzheng Zhao zhanzhengzhao@zzu.edu.cn The first Affiliated Hospital of Zhengzhou University Department of Nephrology zhengzhou China -
Huixia Cao huixiacao310@126.com Henan Provincial People’s Hospital Department of Nephrology zhengzhou China -
Lijie He helijie@fmmu.edu.cn Xijing Hospital of Air Force Medical Department of Nephrology Xi’an China -
Mengli Tong 1994185637@qq.com Hangzhou Traditional Chinese Medicine Hospital of Zhejiang Chinese Medical University Department of Nephrology Hangzhou China -
Xuanyi Du dxy_shennei@126.com The 2nd Affiliated Hospital of Harbin Medical University Department of Nephrology Harbin China -
Yun Liu catdoctor@126.com The First Affiliated Hospital of Henan Medical University Department of Nephrology Xinxiang China -
Gaosi Xu gaosixu@163.com The Second Affiliated Hospital of Nanchang University Department of Nephrology Nanchang China -
Dongsheng Ren 584845792@qq.com Nanyang Central Hospital Department of Nephrology Nanyang China -
Tingjun Zhao 18603622020@126.com The First Hospital of Qiqihar Department of Nephrology Qiqihar China -
Bo Zhang zhangboyufang@163.com Xinyang Central Hospital Department of Nephrology Xinyang China -
Junxia Wang Lyyzwjx@126.com The First Affiliated Hospital of Henan University of Science & Technology Department of Nephrology Luoyang China -
 
 
Membranous nephropathy (MN) is the leading cause of nephrotic syndrome in adults. B-cell hyperactivity plays a crucial role in the pathogenesis of membranous nephropathy. Anti-CD20 monoclonal antibodies are the first-line treatment option for MN as recommended by the KDIGO guidelines. Zuberitamab, an innovative anti-CD20 monoclonal antibody, has shown intense antibody-dependent cellular cytotoxicity. To date, studies assessing MN patients treated with zuberitamab are scarce. This study aims to evaluate the real-world effectiveness and safety of zuberitamab in MN patients.
This multicenter retrospective study enrolled patients from 11 hospitals in China, who were diagnosed with MN and administered treatment with zuberitamab between June 2023 and June 2024. Comprehensive data were meticulously recorded at baseline, 3 months, and 6 months following treatment, encompassing crucial indicators such as 24-hour urinary protein, estimated glomerular filtration rate (eGFR), serum albumin, serum creatinine, CD19+ B-cell count, and serum anti-phospholipase A2 receptor (anti-PLA2R) antibody levels. The primary outcome was the remission rate including complete remission (CR) and partial remission (PR).
Totally 115 MN patients were enrolled, with a mean age of 50.42±12.95 years. The remission rate was 62.6% at 6 months, including a CR rate of 24.3% and a PR rate of 38.3%. Significant reductions were observed in 24-hour urinary protein (P<0.001 for 3 and 6 months), CD19+ B-cell count (P<0.001 for 3 and 6 months) and anti-PLA2R antibody levels (P=0.004 for 3 months; P=0.001 for 6 months) at both 3 and 6 months. Serum albumin levels significantly increased (P<0.001 for 3 and 6 months), with stable serum creatinine and eGFR levels (P>0.05 for both). Baseline eGFR was significantly higher in patients who achieved CR or PR (100.90 [87.94, 115.62] ml/min/1.73 m2) at 6 months compared with those who did not (88.00 [60.59, 101.57] ml/min/1.73 m2, P=0.002); baseline serum albumin levels were also higher in patients who achieved CR or PR (P =0.026). No serious adverse events were detected.
Zuberitamab demonstrated favorable real-world effectiveness and safety in MN patients, with significantly reduced urinary protein levels, particularly in individuals with normal or mildly impaired renal function.
Kewords